Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment (Q38044829)

27 August 2017

Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment (English)

1 reference

27 August 2017

0 references

organ transplantation

1 reference

Elena Beam

1

0 references

author name string

Raymund R Razonable

series ordinal

2

1 reference

27 August 2017

1 December 2012

1 reference

Current infectious disease reports

27 August 2017

1 reference

27 August 2017

14

1 reference

27 August 2017

6

1 reference

27 August 2017

633-641

1 reference

Post-renal transplant cytomegalovirus infection: study of risk factors

27 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Influence of cytomegalovirus disease in outcome of solid organ transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Is cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Clinical usefulness of plasma quantitative polymerase chain reaction assay: diagnosis of cytomegalovirus infection in kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Interlaboratory comparison of cytomegalovirus viral load assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcγRIIIa).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Antiviral drug resistance of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Incidence of cytomegalovirus UL97 and UL54 amino acid substitutions detected after 100 or 200 days of valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Clinical Utility of Cytomegalovirus Cell-Mediated Immunity in Transplant Recipients With Cytomegalovirus Viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11908-012-0292-2

Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants.

21 January 2018

1 reference

12 December 2020

Epidemiology of cytomegalovirus infection after pancreas transplantation

1 reference

12 December 2020

First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246

1 reference

12 December 2020

Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients

1 reference

12 December 2020

Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood

1 reference

12 December 2020

The risk of cytomegalovirus recurrence after kidney transplantation

1 reference

12 December 2020

Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.

1 reference

12 December 2020

[Comparison of the results of quantitative polymerase chain reaction for cytomegalovirus among laboratories].

1 reference

12 December 2020

Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis

1 reference

12 December 2020

Cytomegalovirus incidence between everolimus versus mycophenolate in de novo renal transplants: pooled analysis of three clinical trials

1 reference

12 December 2020

Clinical Utility of Molecular Surveillance for Cytomegalovirus After Antiviral Prophylaxis in High-Risk Solid Organ Transplant Recipients

1 reference

12 December 2020

10.1007/S11908-012-0292-2

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22992839